Literature DB >> 9754946

Recent developments in HIV protease inhibitor therapy.

A Molla1, G R Granneman, E Sun, D J Kempf.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9754946     DOI： 10.1016/s0166-3542(98)00011-4

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  22 in total

1.  BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

Authors:  B S Robinson; K A Riccardi; Y F Gong; Q Guo; D A Stock; W S Blair; B J Terry; C A Deminie; F Djang; R J Colonno; P F Lin
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

2.  Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.

Authors:  Nancy M King; Laurence Melnick; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Shiow-Shong Yang; Yun Gao; Xiaoyi Nie; Charles Zepp; Donald L Heefner; Celia A Schiffer
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

Review 3.  Pharmacokinetic enhancement of protease inhibitor therapy.

Authors:  Jennifer R King; Heather Wynn; Richard Brundage; Edward P Acosta
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.

Authors:  Hongmei Mo; Martin S King; Kathryn King; Akhteruzzaman Molla; Scott Brun; Dale J Kempf
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.

Authors:  D O'Meara; K Wilbe; T Leitner; B Hejdeman; J Albert; J Lundeberg
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

6.  Differential bidirectional transfer of indinavir in the isolated perfused human placenta.

Authors:  Sreeja Sudhakaran; Hany Ghabrial; Roger L Nation; David C M Kong; Neil M Gude; Peter W Angus; Craig R Rayner
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

7.  Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor.

Authors:  P Bossi; M Mouroux; A Yvon; F Bricaire; H Agut; J M Huraux; C Katlama; V Calvez
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

8.  Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.

Authors:  A Hsu; G R Granneman; G Cao; L Carothers; A Japour; T El-Shourbagy; S Dennis; J Berg; K Erdman; J M Leonard; E Sun
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.

Authors:  Madhavi Kolli; Eric Stawiski; Colombe Chappey; Celia A Schiffer
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

10.  Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.

Authors:  Sidonie Lambert-Niclot; Philippe Flandre; Ana Canestri; Gilles Peytavin; Christine Blanc; Rachid Agher; Cathia Soulié; Marc Wirden; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.